A research team reported that simultaneous modulation of STING, TGF‑β, and PD‑L1 pathways markedly enhanced antitumor responses via the CXCL16–CXCR6 signaling axis. The triple‑targeting approach produced stronger immune infiltration and tumor control in preclinical models, suggesting a combinatorial strategy to boost checkpoint efficacy. The study outlines a multi‑axis immunotherapy concept that could inform combination regimens in clinical development. Sponsors will need to consider overlapping toxicities and biomarker strategies to identify patients most likely to benefit from coordinated STING activation, TGF‑β suppression, and PD‑L1 blockade.